Even During Height of Pandemic, Most Did Not Use Prenatal Telehealth
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Oct. 12, 2023 -- Many pregnant individuals who gave birth between June and December 2020 did not use prenatal telehealth, according to a research letter published online Oct. 10 in JAMA Network Open.
Rebecca A. Gourevitch, Ph.D., from the University of Maryland in College Park, and colleagues used results from a multistate survey to examine variation in prenatal telehealth use and reasons for its nonuse at the height of the COVID-19 pandemic. The analysis included responses from 12,073 participants in the 2020 Pregnancy Risk Assessment Monitoring System who gave birth between June and December 2020.
The researchers found that one in three respondents used prenatal telehealth. Use was similar for respondents with private insurance and Medicaid, but uninsured respondents were 14.6 percentage points less likely to use prenatal telehealth. Compared with non-Hispanic White respondents, Hispanic, Asian or Pacific Islander, and Indigenous respondents were more likely to use prenatal telehealth, while participants in rural areas were less likely to use it than urban respondents. Among the 7,686 respondents who did not use prenatal telehealth, personal preference for in-person care (70 percent) was the most reported reason, followed by no appointment availability (26 percent), other reasons (14 percent), and technological barriers (5 percent).
"Our results by insurance type and race and ethnicity are more consistent with national surveys across conditions than with single-site studies of prenatal telehealth, highlighting the importance of multisite research to inform best practices," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Further Support and Information on COVID-19
Read this next
Residual Risk Seen for Death, Postacute Sequelae in Third Year After COVID-19 Hospitalization
THURSDAY, June 13, 2024 -- For individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the risks for death and postacute sequelae of COVID-19...
Systemic Side Effects of COVID-19 Vaccine Tied to Greater nAB Response
TUESDAY, June 11, 2024 -- Short-term systemic side effects of the severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA vaccine are associated with greater long-lasting...
Nirmatrelvir-Ritonavir No Aid for Long COVID Symptoms
MONDAY, June 10, 2024 -- A 15-day course of nirmatrelvir-ritonavir (NMV/r) is safe but does not demonstrate a significant benefit for improving postacute sequelae of SARS-CoV-2...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.